Page 57 - MemoriaBBN-Eng

www.ciber-bbn.es

The presence of these groups improves the thermodynamic stability of the siRNA

duplex. These duplexes can transfect human cells, and the conjugates efficiently
enter in the RNA mechanism of interference, in a similar way to the unmodified

ones, inducing specific inhibition of the gene with the complementary sequence to

the siRNA. Besides, the modified siRNA have a higher stability to nucleases present
in serum than the unmodified ones. Therefore, those described in this invention can

keep the gene silencing for a longer time than those unmodified. Another aspect is
the pharmaceutical compositions containing these siRNA compounds and, at least,

an excipient or pharmaceutical vehicle, and the use of these compounds or their

pharmaceutical compositions for the preparation of drugs.

The excipients include any inert material used for the preparation of a composition
for pharmaceutical dosage. A particular excipient is the transfection agents that

increase the vector properties of the composition. The preferred administration of

the pharmaceutical compositions of this invention is oral or parenteral.

•
NEWDELIVERYSYSTEMOFTHERAPEUTICSTOCOLORECTALCANCERCELLS
European Patent Application EP2011382005.4

International Patent Application PCT/EP2012/050513

National phase in Europe, USA, Japón, China, India, Australia, and Israel

A new drug delivery system for the selective treatment of colorectal tumor cells
has been developed. So far, in vivo delivery tests have been successful, showing

specific and receptor mediated cell internalization of payload vehicles in tumor and

metastasis tissues at low doses. Furthermore, carriers have shown high stability
into the animal, without apparent toxicity.

• OCULARDEVICE

Spanish Patent ES 2370014 B2

International Application PCT/ES2012/070474

US Application number 13/534,583

The present invention describes a device useful for retinal re-attachment and its
post-surgery treatment. It belongs to the micro- and nano-technologies for health

and biomedical applications, particularly to the optimization of ophthalmological

surgery, as well as to patient post-surgery conditions.

The device, provided by this invention, keeps the retinal hole closed and improves
the well-being of patient after surgery. Its components are intra-ocularly injected

and placed in the tear zone closing the retinal holes causing the detachment.

It was tested in rabbits. Results showed a 90% success in the retina re-attachment 13
after one week. Furthermore, no side effects have been detected.
20
T
The high incidence of retinal detachment places this pathology as a priority for OR
P
ophthalmologists, particularly the technological challenge of achieving an efficient RE
L
system to close the break due to retinal hole.
A
NU
N
• OPTIMIZEDHISTOLOGICALMETHODFORTHEPRESERVATIONOF A
N /
EPITOPES AND CELLULAR ARCHITECTURE OF VERTEBRATE TISSUES
B
-B
Spanish Patent ES 2363551 B2
R
BE
This invention develops an optimized new method for the histological and histo- CI

chemical preservation of tissue. This method is compatible with any staining method
for histological sections, as well as for immuno-localization and in situ hybridization.
57